First Live Case in the U.K. Using Cappella's Sideguard(R) Coronary Sidebranch Stent at PCI Live

GALWAY, Ireland, November 25 - Cappella, Inc. (Cappella), a medical device company developing dynamic
solutions for the treatment of coronary bifurcation disease announced the
first U.K. cases involving the Sideguard(R) Coronary Sidebranch Stent &
Delivery System. The initial case was performed at PCI Live 2009 with the
second case following immediately thereafter, off-camera. Dr. Joseph D.
Mills, Consultant Cardiologist at the Liverpool Heart & Chest Hospital, UK
performed both procedures. According to Dr. Mills, "We see numerous
bifurcation cases & are very pleased to see that there is now a dedicated and
straightforward solution to treating complex bifurcation lesions. As the
first centre in the UK to use Sideguard, we are very satisfied with the
results."

To view the Multimedia News Release, please click:
multivu.prnewswire.com/mnr/cappella/41383/

Cappella recently added an additional size of 3.25 to their current
portfolio of 2.5 and 2.75. This now enables treatment of bifurcation lesions
in lumen diameters from 2.25 to 3.25mm and lesion lengths less than or equal
to 7mm. In addition to the new diameter, the product line will be further
expanded according to Dr. Art Rosenthal, CEO, "We will make longer-length
stents available in 2010, enhancing our broad product line and Cappella's
position as the leading company in the treatment of bifurcations."

Cappella also recently expanded its commercial operations in Europe with
the addition of a direct sales force this past month for the UK & Ireland.
Cappella is currently active in Germany, Italy, the Netherlands, Austria &
Switzerland.

About Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions
for the treatment of complex Coronary Artery Disease (CAD) and specifically
bifurcation vascular disease. Cappella's initial product, the Sideguard(R)
Coronary Sidebranch Stent & Delivery System offers interventional
cardiologists a straightforward, effective solution that focuses on treating
the sidebranch of diseased coronary arteries first, rather than the main
vessel. More importantly, it allows the preferred stent of choice for the
main vessel. An optimal stent design specific to the anatomy of the
sidebranch, combined with the qualities of Nitinol now provide a dynamic
solution for treating sidebranch disease. Cappella Medical Devices Ltd.,
Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For
more information, see: www.cappella-med.com.

Links:

Cappella : www.cappella-med.com/

Sideguard(R): www.cappella-med.com/Sideguard.aspx

Dr. Art Rosenthal: www.cappella-med.com/Quality-Leadership.aspx

3.25: www.cappella-med.com/cuuploads/editor/file/2009_002_EN%20Sideguard%20Flyer_LR.pdf

(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)

    Contact:

    Claire Marie Gigon
    Cappella Medical Devices Limited
    Tel: +41(0)79-374-57-65
    Email: cmgigon@cappella.ie

Contact: Claire Marie Gigon, Cappella Medical Devices Limited, Tel: +41(0)79-374-57-65, Email: cmgigon at cappella.ie